Arvinas (ARVN) Equity Income (2019 - 2020)
Arvinas' (ARVN) quarterly Equity Income came in at -$1.4 million in Q2 2020, down 227.27% quarter-over-quarter from $1.1 million in Q1 2020.
Arvinas (ARVN) Equity Income (2019 - 2020) Analysis & Trends
Arvinas' Equity Income history runs 2 years deep, the most recent figure standing at -$1.4 million for Q2 2020.
- On a quarterly basis, Equity Income changed N/A year-over-year to -$1.4 million in Q2 2020; TTM through Jun 2020 was $49.5 million, a N/A change from a year earlier, with the FY2019 full-year figure at $49.8 million, changed N/A from the prior year.
- Equity Income retreated to -$1.4 million in Q2 2020 per ARVN's latest filing, from $1.1 million in the prior quarter.
- Across five years, Equity Income topped out at $99.3 million in Q4 2019 and bottomed at -$49.5 million in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -1.40 Mn |
| Mar 31, 2020 | 1.10 Mn |
| Dec 31, 2019 | 99.30 Mn |
| Sep 30, 2019 | -49.50 Mn |